Ubs Group Ag In Med Pharmaceuticals Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INM
# of Institutions
16Shares Held
1.14MCall Options Held
0Put Options Held
0-
Advisor Shares Investments LLC Bethesda, MD733KShares$3.42 Million0.03% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il56.7KShares$264,0630.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny50.3KShares$234,3790.0% of portfolio
-
Hrt Financial LP New York, NY38.4KShares$178,7990.0% of portfolio
-
Virtu Financial LLC New York, NY28.4KShares$132,4130.0% of portfolio
About InMed Pharmaceuticals Inc.
- Ticker INM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 908,761
- Market Cap $4.23M
- Description
- InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in precl...